Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;12(8):805-816.
doi: 10.1002/pmrj.12291. Epub 2020 Jan 14.

Use of Adipose-Derived Orthobiologics for Musculoskeletal Injuries: A Narrative Review

Allison Schroeder  1 , J Peter Rubin  2   3   4 , Lauren Kokai  2   4 , Gwendolyn Sowa  1   5 , Joseph Chen  6 , Kentaro Onishi  1   5
Affiliations
Review

Use of Adipose-Derived Orthobiologics for Musculoskeletal Injuries: A Narrative Review

Allison Schroeder et al. PM R. 2020 Aug.

Abstract

Musculoskeletal injuries are among the most prevalent, disabling, and costly conditions that Americans face, affecting over half of those over 18 and nearly 75% of those over 65 years old. Current treatments are largely palliative for many of these conditions and unmet needs have warranted the emergence of alternative treatments. Orthobiologics, such as adipose tissue derivatives (ATDs), are of high interest because they can be obtained in the office setting and their cellular components, including adipose stem cells and stromal cells, are thought to be beneficial in the treatment of musculoskeletal injuries. Microfragmented adipose tissue (MFAT) and stromal vascular fraction (SVF) are two ATD injectates that are used in the clinical setting to treat musculoskeletal conditions. Our review aimed to clarify the terminology describing the various ATDs used for orthopedic indications while discussing the promising but low-quality evidence, heterogeneity in MFAT and SVF processing methods, and inconsistencies in reported information such as injectate characterization with cell counts, injection technique, and postprocedural rehabilitation.

PubMed Disclaimer

References

    1. The Burden of Musculoskeletal Diseases in the United States. http://www.boneandjointburden.org/.
    1. Weinstein SL. 2000-2010: the bone and joint decade. J Bone Joint Surg Am. 2000;82(1):1-3.
    1. Alderman DD, Alexander RW. Advances in regenerative medicine: high-density platelet-rich plasma and stem cell prolotherapy for musculoskeletal pain. Pract Pain Manag. 2011;11(8):49-63.
    1. Oberbauer E, Steffenhagen C, Wurzer C, Gabriel C, Redl H, Wolbank S. Enzymatic and non-enzymatic isolation systems for adipose tissue-derived cells: current state of the art. Cell Regen (Lond). 2015;4:7.
    1. U.S. Food and Drug Administration. Same surgical procedure exception under 21 CFR 1271.15 (b): questions and answers regarding the scope of the exception, guidance for industry. https://www.fda.gov/media/89920/download. Accessed November, 2017.